Timing of Moderate to Vigorous Physical Activity, Mortality, Cardiovascular Disease, and Microvascular Disease in Adults With Obesity
- PMID: 38592034
- PMCID: PMC11043226
- DOI: 10.2337/dc23-2448
Timing of Moderate to Vigorous Physical Activity, Mortality, Cardiovascular Disease, and Microvascular Disease in Adults With Obesity
Abstract
Objective: To assess the association between timing of aerobic moderate to vigorous physical activity (MVPA) and risk of cardiovascular disease (CVD), microvascular disease (MVD), and all-cause mortality in adults with obesity and a subset with obesity and type 2 diabetes (T2D).
Research design and methods: Participants included adults with obesity (BMI ≥30 kg/m2) and a subset of those with T2D from the UK Biobank accelerometry substudy. Aerobic MVPA was defined as bouts of MVPA lasting ≥3 continuous minutes. Participants were categorized into morning, afternoon, or evening MVPA based on when they undertook the majority of their aerobic MVPA. The reference group included participants with an average of less than one aerobic MVPA bout per day. Analyses were adjusted for established and potential confounders.
Results: The core sample included 29,836 adults with obesity, with a mean age of 62.2 (SD 7.7) years. Over a mean follow-up period of 7.9 (SD 0.8) years, 1,425 deaths, 3,980 CVD events, and 2,162 MVD events occurred. Compared with activity in the reference group, evening MVPA was associated with the lowest risk of mortality (hazard ratio [HR] 0.39; 95% CI 0.27, 0.55), whereas afternoon (HR 0.60; 95% CI 0.51, 0.71) and morning MVPA (HR 0.67; 95% CI 0.56, 0.79) demonstrated significant but weaker associations. Similar patterns were observed for CVD and MVD incidence, with evening MVPA associated with the lowest risk of CVD (HR 0.64; 95% CI 0.54, 0.75) and MVD (HR 0.76; 95% CI 0.63, 0.92). Findings were similar in the T2D subset (n = 2,995).
Conclusions: Aerobic MVPA bouts undertaken in the evening were associated with the lowest risk of mortality, CVD, and MVD. Timing of physical activity may play a role in the future of obesity and T2D management.
© 2024 by the American Diabetes Association.
Conflict of interest statement
Figures
Similar articles
-
Association of Objectively Measured Timing of Physical Activity Bouts With Cardiovascular Health in Type 2 Diabetes.Diabetes Care. 2021 Apr;44(4):1046-1054. doi: 10.2337/dc20-2178. Epub 2021 Feb 17. Diabetes Care. 2021. PMID: 33597215 Free PMC article.
-
Timing of physical activity in relation to liver fat content and insulin resistance.Diabetologia. 2023 Mar;66(3):461-471. doi: 10.1007/s00125-022-05813-3. Epub 2022 Nov 1. Diabetologia. 2023. PMID: 36316401 Free PMC article.
-
Association of physical activity intensity and bout length with mortality: An observational study of 79,503 UK Biobank participants.PLoS Med. 2021 Sep 15;18(9):e1003757. doi: 10.1371/journal.pmed.1003757. eCollection 2021 Sep. PLoS Med. 2021. PMID: 34525088 Free PMC article.
-
Device-measured physical activity, sedentary time, and risk of all-cause mortality: an individual participant data analysis of four prospective cohort studies.Br J Sports Med. 2023 Nov;57(22):1457-1463. doi: 10.1136/bjsports-2022-106568. Epub 2023 Oct 24. Br J Sports Med. 2023. PMID: 37875329 Review.
-
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013556. doi: 10.1002/14651858.CD013556.pub2. Cochrane Database Syst Rev. 2022. PMID: 35199850 Free PMC article. Review.
References
-
- Powell-Wiley TM, Poirier P, Burke LE, et al. ; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council . Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2021;143:e984–e1010 - PMC - PubMed
-
- Suren Garg S, Kushwaha K, Dubey R, Gupta J. Association between obesity, inflammation and insulin resistance: insights into signaling pathways and therapeutic interventions. Diabetes Res Clin Pract 2023;200:110691. - PubMed
-
- Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010–1013 - PubMed